GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Lixisenatide shows no effect on arterial stiffness in type 2 diabetes with chronic kidney disease
Study finds diabetes drug lixisenatide did not improve artery stiffness in kidney disease patients
A single-center, proof-of-concept randomized controlled trial in 90 people with type 2 diabetes and chronic kidney disease found that 24 wee…
A diabetes drug did not soften arteries in people with kidney disease, showing no improvement in a key heart risk factor after 24 weeks of t…
FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities
The FDA has approved a new daily pill called FOUNDAYO to help adults manage their weight
The FDA has approved FOUNDAYO (orforglipron), an oral GLP-1 receptor agonist, for chronic weight management in adults with obesity or overwe…
FDA approves new daily pill FOUNDAYO for adults to manage weight alongside diet and exercise.